BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11968579)

  • 1. [Hyperinsulinemia and disorders of the menstrual cycle].
    Dravecká I; Lazúrová I; Kraus V; Petrovicová J; Paĺko M
    Vnitr Lek; 2002 Mar; 48(3):192-6. PubMed ID: 11968579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome: obesity, insulin resistance, hyperandrogenism.
    Lo Dico G; Alongi G; Savatteri L; Rini GB; Mascellino MR; Di Fede G; Rizzo G
    Acta Eur Fertil; 1989; 20(5):309-13. PubMed ID: 2700062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose intolerance in Japanese patients with polycystic ovary syndrome.
    Kurioka H; Takahashi K; Miyazaki K
    Arch Gynecol Obstet; 2007 Mar; 275(3):169-73. PubMed ID: 16972071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases].
    Hu WH; Qiao J; Li MZ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):721-4. PubMed ID: 17565837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
    Panidis D; Rousso D; Koliakos G; Kourtis A; Katsikis I; Farmakiotis D; Votsi E; Diamanti-Kandarakis E
    Fertil Steril; 2006 Jun; 85(6):1778-83. PubMed ID: 16650418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.
    Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
    Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity is the major factor determining an insulin sensitivity and androgen production in women with anovulary cycles.
    Dravecka I; Lazurova I; Kraus V
    Bratisl Lek Listy; 2003; 104(12):393-9. PubMed ID: 15053331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
    Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia.
    Dunaif A; Graf M; Mandeli J; Laumas V; Dobrjansky A
    J Clin Endocrinol Metab; 1987 Sep; 65(3):499-507. PubMed ID: 3305551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
    Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF
    Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
    J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
    Liu ZA; Xue YM; Chen LX; Cai Q; Chen H; Zhang J; Cui QH; Ge J; Yuan T
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.